These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33854062)

  • 1. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling.
    Huang H; Hu J; Maryam A; Huang Q; Zhang Y; Ramakrishnan S; Li J; Ma H; Ma VWS; Cheuk W; So GYK; Wang W; Cho WCS; Zhang L; Chan KM; Wang X; Chin YR
    Nat Commun; 2021 Apr; 12(1):2242. PubMed ID: 33854062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super-enhancer acquisition drives oncogene expression in triple negative breast cancer.
    Raisner R; Bainer R; Haverty PM; Benedetti KL; Gascoigne KE
    PLoS One; 2020; 15(6):e0235343. PubMed ID: 32584896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
    Hu J; Lai Y; Huang H; Ramakrishnan S; Pan Y; Ma VWS; Cheuk W; So GYK; He Q; Geoffrey Lau C; Zhang L; Cho WCS; Chan KM; Wang X; Rebecca Chin Y
    Br J Cancer; 2022 Jan; 126(1):57-71. PubMed ID: 34718356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.
    Sim N; Carter JM; Deka K; Tan BKT; Sim Y; Tan SM; Li Y
    Nat Commun; 2024 Jul; 15(1):5638. PubMed ID: 38965263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
    Franco HL; Nagari A; Malladi VS; Li W; Xi Y; Richardson D; Allton KL; Tanaka K; Li J; Murakami S; Keyomarsi K; Bedford MT; Shi X; Li W; Barton MC; Dent SYR; Kraus WL
    Genome Res; 2018 Feb; 28(2):159-170. PubMed ID: 29273624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer.
    Han B; Zhou B; Qu Y; Gao B; Xu Y; Chung S; Tanaka H; Yang W; Giuliano AE; Cui X
    Oncogene; 2018 Mar; 37(10):1399-1408. PubMed ID: 29249801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
    Guo P; Yang J; Huang J; Auguste DT; Moses MA
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANLN Enhances Triple-Negative Breast Cancer Stemness Through TWIST1 and BMP2 and Promotes its Spheroid Growth.
    Maryam A; Chin YR
    Front Mol Biosci; 2021; 8():700973. PubMed ID: 34277708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK7-dependent transcriptional addiction in triple-negative breast cancer.
    Wang Y; Zhang T; Kwiatkowski N; Abraham BJ; Lee TI; Xie S; Yuzugullu H; Von T; Li H; Lin Z; Stover DG; Lim E; Wang ZC; Iglehart JD; Young RA; Gray NS; Zhao JJ
    Cell; 2015 Sep; 163(1):174-86. PubMed ID: 26406377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of FOXC1/FOXCUT/DANCR axis in triple negative breast cancer: a bioinformatics and experimental approach.
    Kamaliyan Z; Mirfakhraie R; Azizi-Tabesh G; Darbeheshti F; Omranipour R; Ahmadinejad N; Zokaei E; Yassaee VR
    Mol Biol Rep; 2022 Apr; 49(4):2821-2829. PubMed ID: 35066769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic transcription factors instruct promoter-enhancer hubs in individual triple negative breast cancer cells.
    Zhao J; Zhou Y; Tzelepis I; Burget NG; Shi J; Faryabi RB
    Sci Adv; 2024 Aug; 10(32):eadl4043. PubMed ID: 39110799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.
    Hsu YH; Yao J; Chan LC; Wu TJ; Hsu JL; Fang YF; Wei Y; Wu Y; Huang WC; Liu CL; Chang YC; Wang MY; Li CW; Shen J; Chen MK; Sahin AA; Sood A; Mills GB; Yu D; Hortobagyi GN; Hung MC
    Cancer Res; 2014 Sep; 74(17):4822-35. PubMed ID: 24970481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
    Zheng S; Yang L; Zou Y; Liang JY; Liu P; Gao G; Yang A; Tang H; Xie X
    J Hematol Oncol; 2020 Mar; 13(1):17. PubMed ID: 32138762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
    Di Benedetto C; Oh J; Choudhery Z; Shi W; Valdes G; Betancur P
    BMC Cancer; 2022 Oct; 22(1):1056. PubMed ID: 36224576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.